These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 33010471)

  • 1. Dysregulated lipid metabolism links NAFLD to cardiovascular disease.
    Deprince A; Haas JT; Staels B
    Mol Metab; 2020 Dec; 42():101092. PubMed ID: 33010471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases.
    Dabravolski SA; Bezsonov EE; Baig MS; Popkova TV; Orekhov AN
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
    Simon TG; Corey KE; Chung RT; Giugliano R
    Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease.
    Corey KE; Vuppalanchi R; Vos M; Kohli R; Molleston JP; Wilson L; Unalp-Arida A; Cummings OW; Lavine JE; Chalasani N;
    J Pediatr Gastroenterol Nutr; 2015 Mar; 60(3):360-7. PubMed ID: 25714579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the association between developing a fatty liver and subsequent cardio-metabolic complications.
    Miele L; Targher G
    Expert Rev Gastroenterol Hepatol; 2015; 9(10):1243-5. PubMed ID: 26224399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.
    Cohen DE; Fisher EA
    Semin Liver Dis; 2013 Nov; 33(4):380-8. PubMed ID: 24222095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors.
    Muzurović E; Peng CC; Belanger MJ; Sanoudou D; Mikhailidis DP; Mantzoros CS
    Hypertension; 2022 Jul; 79(7):1319-1326. PubMed ID: 35465684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease and cardiovascular disease.
    Liu H; Lu HY
    World J Gastroenterol; 2014 Jul; 20(26):8407-15. PubMed ID: 25024598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders.
    Lim S; Oh TJ; Koh KK
    Int J Cardiol; 2015 Dec; 201():408-14. PubMed ID: 26310987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyslipidemia in patients with nonalcoholic fatty liver disease.
    Chatrath H; Vuppalanchi R; Chalasani N
    Semin Liver Dis; 2012 Feb; 32(1):22-9. PubMed ID: 22418885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease.
    Martin A; Lang S; Goeser T; Demir M; Steffen HM; Kasper P
    Curr Atheroscler Rep; 2022 Jul; 24(7):533-546. PubMed ID: 35507279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
    Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
    J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases.
    Vural H; Armutcu F; Akyol O; Weiskirchen R
    Clin Chim Acta; 2021 Dec; 523():374-379. PubMed ID: 34678296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive assessment of hepatic lipid subspecies matched with non-alcoholic fatty liver disease phenotype.
    Erickson ML; Haus JM; Malin SK; Flask CA; McCullough AJ; Kirwan JP
    Nutr Metab Cardiovasc Dis; 2019 Nov; 29(11):1197-1204. PubMed ID: 31371265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease and cardiovascular disease.
    Hyogo H; Chayama K; Yamagishi S
    Curr Pharm Des; 2014; 20(14):2403-11. PubMed ID: 23844815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease.
    Zelber-Sagi S; Salomone F; Yeshua H; Lotan R; Webb M; Halpern Z; Santo E; Oren R; Shibolet O
    Liver Int; 2014 Jul; 34(6):e128-35. PubMed ID: 24118857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.
    Milić S; Lulić D; Štimac D
    World J Gastroenterol; 2014 Jul; 20(28):9330-7. PubMed ID: 25071327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into the pathophysiology of dyslipidemia in type 2 diabetes.
    Taskinen MR; Borén J
    Atherosclerosis; 2015 Apr; 239(2):483-95. PubMed ID: 25706066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.